Insights
Insights From Our Experts
Articles
Elevate Your Brand to New Heights by Utilizing National Account Managers’ Singular Skills, Resources and Experience in an Ever-changing Marketplace
Launching new therapies is a vast undertaking for any pharmaceutical company. Setting up a product for success requires a great deal of expense, research, strategic planning and effective collaboration, just to name a few essential elements. EVERSANA’s National…
The New Role of Medical Field Teams and Their Impact on Launch Success
A combination of industry challenges and an influx of complex therapies in the market, have impacted Medical Science Liaisons (MSLs), Clinical Trial Liaisons (CTLs) and Clinical Nurse Educators (CNEs). Susan Giacalone, MSN, BCMAS, MSL-BC, Vice President,…
How Specialty Pharmacies Can Elevate Your Channel and Distribution Strategy for HCP-administered Buy & Bill Products
A successful channel and distribution strategy for Buy & Bill (B&B) products should be centered around the partners you sell to and through. That means considering any third-party logistics (3PL) providers, specialty distributors (SD) and specialty…
AMA Scheduled to Deliberate Potential Approval of Additional Digital Medicine CPT Codes
As part of its upcoming meeting in mid-September, members of the American Medical Association’s (AMA) CPT Editorial Panel will consider several new Current Procedural Terminology (CPT) codes that identify digital diagnostic and therapeutic procedures. Between this…
Reimbursement Landscape for Digital Medicine Continues to Advance with CMS
The Centers for Medicare and Medicaid Services (CMS) recently announced several new payment and coding proposals that, once finalized, would recognize and advance the use of digital diagnostic and therapeutic modalities. In this week’s update, we…
Innovative Payer Strategies Demand Innovative NAM Strategies
EVERSANA’s Rich Heddens, Senior Vice President, Payer Strategy & Execution, and Dino Tsamparlis, Vice President, Market Access, discuss how innovative payer strategies call for innovative National Account Manager (NAM) strategies. The industry is facing unique challenges…
Plasma derived medicinal products – What is the way forward?
Content for this article was contributed by the EVERSANA Asia Pacific team. Plasma-derived products have a long history of providing benefits, especially in fractions addressing coagulation. Plasma is a rich biological substance and one of the…
EVERSANA’s Value & Evidence Team’s Work Tops List of Most Read Articles in 2021 in Journal of Comparative Effectiveness Research
If you work in the field of Health Economics and Outcome Research (HEOR) in the life sciences industry, you know just how valuable the Journal of Comparative Effectiveness Research (JCER) is. The publication features peer-reviewed studies…
Social Determinants of Health – What Pharma Can Do!
The US Department of Health and Human Services defines Social Determinants of Health (SDoH) as conditions in the places where people live, learn, work, and play that affect a wide range of health risks and outcomes.1…
Three Keys to Value for Unlocking the Promise of Cell Therapies
The cell therapy market continues to grow. Estimated at $101 billion in 2021, the global cell therapy market is projected to reach $247 billion by 2028, a CAGR of 13.64%.1 The revenue generation is being driven…